Biosimilars
Page 1 • 12 itemsTrack global biosimilar approvals, market entry strategies, and regulatory pathways. Gain critical intelligence for your pharmaceutical BD and investment decisions.
FDA Approves LANGLARA Interchangeable Biosimilar to Lantus Insulin - Lannett Company Receives Key Diabetes Drug Approval
FDA approves LANGLARA (insulin glargine-aldy) as interchangeable biosimilar to Lantus for diabetes treatment in adults and pediatric patients.
Biosimilar Uptake EU: Market Impact Post-Patent Expirations & HTA Regulation
This article examines how biosimilar adoption in the EU is reshaping the market landscape for biologics like Adalimumab after patent expirations and under HTA regulations.
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
The upcoming EU pharmaceutical legislation reform will significantly affect generics and biosimilars, shaping the future of drug access and innovation in 2026-27.
European Commission Approves POHERDY, First Pertuzumab Biosimilar in Europe by Henlius and Organon
EC grants marketing authorization for POHERDY (pertuzumab), the first approved biosimilar to PERJETA in Europe, developed by Henlius Biotech and Organon.
Henlius and Organon's POHERDY Becomes First Pertuzumab Biosimilar Approved in Europe
European Commission approves POHERDY as first pertuzumab biosimilar in Europe, offering cost-effective alternative to PERJETA for breast cancer treatment.
Biosimilars Growth in EU: Market Forecast Post-Biologics Patent Expiry
This article analyzes the anticipated growth of biosimilars in the EU following the patent expiry of major biologics, including Humira for rheumatoid arthritis.
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
This article delves into the market dynamics of biosimilar oncology antibodies, focusing on their role in cancer treatment and implications for healthcare systems.
![EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing](/uploads/articles/ema-biosimilar-approvals-specific-drug-market-analysis-2024.webp)
EMA Biosimilar Approvals 2024: Impact on [Specific Drug] Market & Pricing
Discover how the 2024 EMA biosimilar approvals will affect the market dynamics and pricing strategies for [Specific Drug] used in treating [Indication].
EU Pharmaceutical Legislation Reform: Impact on Biosimilar Market Access & Competition
The recent EU pharmaceutical legislation reform aims to enhance biosimilar market access and competition, significantly affecting drugs like Adalimumab for autoimmune treatments.
EU Pharmaceutical Legislation Reform: Impact on Generics & Biosimilars 2026-27
The upcoming EU Pharmaceutical Legislation Reform will significantly influence the generics and biosimilars market, affecting drug availability and competition.
EU Pharmaceutical Legislation Impact: Biosimilar Market Entry & Competition 2027
This article examines how upcoming EU pharmaceutical legislation will influence the biosimilar market, focusing on Adalimumab and competition dynamics by 2027.
Biocon Receives Health Canada Approval for Denosumab Biosimilars Bosaya and Vevzuo
Health Canada approves Biocon's denosumab biosimilars Bosaya and Vevzuo as alternatives to Prolia and Xgeva for osteoporosis and cancer treatment.